Abstract
Purpose
To diagnose polycystic ovary syndrome (PCOS) in young infertile women using different diagnostic criteria. To define serum anti-Müllerian hormone (AMH) cutoff values for PCOS definition. To investigate the correlation between AMH and body mass index (BMI).
Methods
Retrospective case–control study. A total of 140 infertile women (age 21–35 years) were enrolled. PCOS was defined according to the National Institutes of Health (NIH) criteria, the Rotterdam consensus criteria and the Androgen Excess and PCOS Society (AE-PCOS) criteria. ROC curve analysis was performed to define AMH thresholds for PCOS definition according to the three different diagnostic criteria. Correlation between AMH and BMI was investigated.
Results
The prevalence of PCOS under the NIH criteria, the Rotterdam criteria and the AE-PCOS criteria was 27.1, 40 and 29.3%, respectively. The optimal thresholds of AMH to distinguish NIH PCOS from infertile controls was 5.20 ng/ml (AUC = 0.86, sensitivity 79%, specificity 80%); the best cutoff to detect Rotterdam PCOS was 4.57 ng/ml (AUC = 0.85, sensitivity 78%, specificity 81%); a cutoff of 4.85 ng/ml (AUC = 0.85, sensitivity 80%, specificity 78%) defined PCOS women according to AE-PCOS criteria. The prevalence of the syndrome became 37.1, 44.3 and 39.2% according to the three criteria, respectively, using AMH threshold between 4.57 and 5.20 ng/ml as an alternative to antral follicle count and/or hyperandrogenism.
Conclusion
Anti-Müllerian hormone may reconcile the three diagnostic criteria and allow the PCOS diagnosis in women with mild symptoms. No significant correlation was found between AMH and BMI in PCOS women and controls.
Similar content being viewed by others
References
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008) Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 89:505–522
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W et al (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91:456–488
Boomsma CM, Eijkemans MJC, Hughes EG, Visser GHA, Fauser BCJM, Macklon NS (2006) A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 12:673–683
Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W et al (2010) Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 95:2038–2049
Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R et al (2012) Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Hum Reprod 27:14–24
Barry JA, Azizia MM, Hardiman PJ (2014) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 20:748–758
Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GE (eds) Polycystic ovary syndrome. Blackwell Scientific Publications, Boston, pp 377–384
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25
Ape M, Badoglu B, Akca A, Api O, Gorgen H, Cetin A (2009) Interobserver variability of modified Ferriman–Gallwey hirsutism score in a Turkish population. Arch Gynecol Obstet 279:473–479
Singh AK, Singh R (2015) Can anti-Mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress. Indian J Endocr Metab 19:731–743
Dewailly D, Pigny P, Soudan B, Catteau-Jonard S, Decanter C, Poncelet E et al (2010) Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab 95:4399–4405
Sahmay S, Aydin Y, Oncul M, Senturk L (2014) Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet 31:213–220
Shayya R, Chang RJ (2010) Reproductive endocrinology of adolescent polycystic ovary syndrome. BJOG 117:150–155
Kriseman M, Mills C, Kovanci E, Sangi-Haghpeykar H, Gibbons W (2015) Antimullerian hormone levels are inversely associated with body mass index (BMI) in women with polycystic ovary syndrome. J Assist Reprod Genet 32:1313–1316
Lefebvre T, Dumont A, Pigny P, Dewailly D (2017) Effect of obesity and its related metabolic factors on serum anti-Müllerian hormone concentrations in women with and without polycystic ovaries. Reprod Biomed Online 35:325–330
Skałba P, Cygal A, Madej P, Dąbkowska-Huć A, Sikora J, Martirosian G et al (2011) Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 158:254–259
Cui Y, Shi Y, Cui L, Han T, Gao X, Chen ZJ (2014) Age-specific serum antimüllerian hormone levels in women with and without polycystic ovary syndrome. Fertil Steril 102(230–236):e2
Feldman RA, O’Neill K, Butts SF, Dokras A (2017) Antimüllerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome. Fertil Steril 107:276–281
Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D (2009) Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 296:E238–E243
Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ et al (2009) The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 24:1976–1981
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497
National Institutes of Health (2012) Evidence-based methodology workshop on polycystic ovary syndrome. National Institutes of Health, Washington. https://prevention.nih.gov/p2p/pcos/resources.aspx. Accessed 3–5 Dec 2012
Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H (2012) Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 27:3067–3073
Casadei L, Madrigale A, Puca F, Manicuti C, Emidi E, Piccione E et al (2013) The role of serum anti-Müllerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome. Gynecol Endocrinol 29:545–550
Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM (2013) Can anti-Müllerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 98:3332–3340
Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P et al (2011) Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 26:3123–3129
Fraissinet A, Robin G, Pigny P, Lefebvre T, Catteau-Jonard S, Dewailly D (2017) Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Hum Reprod 32:1716–1722
Pigny P, Gorisse E, Ghulam A, Robin G, Catteau-Jonard S, Duhamel A et al (2016) Comparative assessment of five serum antimüllerian hormone assays for the diagnosis of polycystic ovary syndrome. Fertil Steril 105(1063–69):e3
Pellat L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S et al (2007) Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 92:240–245
Kominiarek MA, Jungheim ES, Hoeger KM, Rogers AM, Kahan S, Kim JJ (2017) American Society for Metabolic and Bariatric Surgery position statement on the impact of obesity and obesity treatment on fertility and fertility therapy Endorsed by the American College of Obstetricians and Gynecologists and the Obesity Society. Surg Obes Relat Dis 13:750–757
Simões-Pereira J, Nunes J, Aguiar A, Sousa S, Rodrigues C, Matias Sampaio et al (2018) Influence of body mass index in anti-Müllerian hormone levels in 951 non-polycystic ovarian syndrome women followed at a reproductive medicine unit. Endocrine. https://doi.org/10.1007/s12020-018-1555-y
Funding
This retrospective study was not funded.
Author information
Authors and Affiliations
Contributions
L Casadei: Protocol/project development, data collection and management, data analysis, manuscript writing/editing. F Fanisio: Protocol/project development, data collection, data analysis, manuscript writing/editing. R P Sorge: Data analysis. M Collamarini: Data collection, manuscript writing/editing. E Piccolo: Data collection, manuscript writing/editing. E Piccione: Protocol/project development
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Institutional Review Board of Tor Vergata University Hospital in accordance with Helsinki Declaration, approved the present study.
Informed consent
Informed consent was obtained from all individual participants included in the study for the processing of the sensitive data.
Rights and permissions
About this article
Cite this article
Casadei, L., Fanisio, F., Sorge, R.P. et al. The diagnosis of PCOS in young infertile women according to different diagnostic criteria: the role of serum anti-Müllerian hormone. Arch Gynecol Obstet 298, 207–215 (2018). https://doi.org/10.1007/s00404-018-4803-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-018-4803-8